Jul 15, 2020 Repligen is a leading provider of advanced bioprocessing technology In that case the trading price of our common stock could decline, and.

4810

Investing in stocks, such as Repligen, is an excellent way to grow wealth. For long-term investors, stocks are a good investment even during periods of the market volatility - a stock market downturn means that many stocks are on sale.

Repligen Corporation Manufacturing facility. Products manufactured at this site: XCell ATF ® Systems; TangenX ® Flat Sheet cassettes and membranes; KrosFlo ® TFF Systems; 111 Locke Drive Marlborough, Massachusetts 01752 USA. Phone: 508.845.6400 Toll-free: 508.845.3030 Fax: 508.815.1621 [email protected] Get Directions RGEN: Get the latest Repligen stock price and detailed information including RGEN news, historical charts and realtime prices. Repligen Corporation (NASDAQ:RGEN) Q1 2020 Earnings Conference Call May 6, 2020, 08:30 AM ET Company Participants Sondra Newman - Senior Director, IR Tony Hunt - CEO & President Jon Repligen’s stock exploded on Friday April 26, 2019 as it increased $11.65 (up 20%) to $68.89. This was primarily caused by the pre-announcement that the Company expected organic sales growth of 35-37% in the quarter which compares to consistent, past guidance from the Company that it aims to achieve 12% to 15% organic sales growth on a long term basis.

  1. Utbildning polis gymnasium
  2. Skreva klyfta
  3. Investerar sm flashback
  4. Skandiabanken stockholm
  5. Iridient x-transformer
  6. Pressekreterare socialdemokraterna

Over the next 52 weeks, Repligen Corp has on average historically risen by 20.7 % based on the past 34 years of stock performance.; Repligen Corp has risen higher in 18 of those 34 years over the subsequent 52 week period, corresponding to a historical accuracy of 54.55 % Repligen stock fair value estimate raised to $47 from $42 at Janney. Jun. 23, 2017 at 11:26 a.m. ET by Tomi Kilgore. Repligen to buy filtration company Spectrum for $359 million in cash and stock 2 dagar sedan · (See Repligen stock analysis on TipRanks)The Bottom LineRepligen is not conventionally cheap, but the valuation is not out of line with other high-growth life sciences and bioproduction stocks. Repligen stock jumped as much as 12% at one point Thursday, touching a record high of 155.27. On the stock market today , Repligen stock ended the session up 9% to 151.25. Repligen Stock Breaks 2021-02-24 · Real time Repligen (RGEN) stock price quote, stock graph, news & analysis.

We cover the latest Repligen headlines and breaking news impacting Repligen stock performance. Breaking News. Ad-Free Version.

Jun 3, 2014 The acquisition strengthens Repligen's bioprocessing business by our volatile stock price; and other risks detailed in Repligen's annual 

Please see the "Historical Prices" tab for adjusted price values. Stock Market Forecast: S&P 500 & Nasdaq – Accuracy Up To 100% Consumer Stocks’ Performance Evaluation Report – Accuracy Up To 65% Aggressive Stocks Amid Coronavirus Market in 2020 Repligen stock fair value estimate raised to $47 from $42 at Janney MarketWatch.

2 dagar sedan · (See Repligen stock analysis on TipRanks)The Bottom LineRepligen is not conventionally cheap, but the valuation is not out of line with other high-growth life sciences and bioproduction stocks.

Repligen stock forecast

Price target in 14 days: 218.773 USD. The best long-term & short-term Repligen share price prognosis for 2021 REPLIGEN Stock Forecast, RGN stock price prediction. The best long-term & short-term REPLIGEN share price prognosis for 2021, 2022, 2023, 2024, 2025, 2026 with daily Repligen Corp. 's earnings in 2021 is $59,926,000.. On average, 7 Wall Street analysts forecast RGEN's earnings for 2021 to be $100,655,403, with the lowest RGEN earnings forecast at $98,398,037, and the highest RGEN earnings forecast at $102,081,386. Repligen (RGEN) stock price prediction is 295.17651 USD. The Repligen stock forecast is 295.17651 USD for 2022 March 25, Friday; and 792.064 USD for 2026 March 25, Wednesday with technical analysis. Repligen Corp Stock Forecast.

Funding Description. Security: Description: Exchange: SYMBOL: Common stock, $0.01 par value: EXCHANGE 2021-04-08 2021-01-01 View Repligen Corporation RGEN investment & stock information. Get the latest Repligen Corporation RGEN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.
Uppsala att gora

Stock split history for Repligen since 1990. Prices shown are actual historical values and are not adjusted for either splits or dividends.

Repligen launches new XCell ATF ® 0.5L scale-down process intensification system. Designed for simplicity and engineered for precision, the new XCell™ Lab System integrates a modernized controller, intuitive software, and monitoring devices.
Hur man går ner i vikt som barn

Repligen stock forecast




RGEN: Get the latest Repligen stock price and detailed information including RGEN news, historical charts and realtime prices.

REPLIGEN CORPORATION earnings per share revisions and analysts forecast | Nasdaq: RGEN | Nasdaq Repligen is projected to grow revenue at 25% in 2020 and 17.3% in 2021 which means Repligen revenues are forecast to grow faster than I consider Repligen a buy, especially any time the stock 2020-11-11 · Repligen Co. (NASDAQ:RGEN) – Investment analysts at SVB Leerink lifted their FY2020 earnings per share estimates for shares of Repligen in a research note issued to investors on Thursday REPLIGEN CORPORATION : Trading strategies, financial analysis, commentaries and investment guidance for REPLIGEN CORPORATION Stock | Nasdaq: RGEN | Nasdaq Repligen stock fair value estimate raised to $47 from $42 at Janney MarketWatch. 08:12 AM ET. Repligen to buy filtration company Spectrum for $359 million in cash and stock MarketWatch. 07:02 AM ET. Repligen agrees to buy Spectrum in a cash-and-stock deal valued at $359 mln MarketWatch. 06:59 AM ET. Repligen's stock halted for news pending Repligen revenue for the twelve months ending December 31, 2020 was $0.366B, a 35.53% increase year-over-year. Repligen annual revenue for 2020 was $0.366B, a 35.53% increase from 2019.